Dividends & Buybacks ·
NeuroSense reports $3.6M net loss, holds $231K cash amid going concern doubt; PrimeC hits primary endpoints in ALS study
NRSNWNeuroSense Therapeutics Ltd.
NeuroSense Therapeutics filed its Q2 2026 financials and business update, reporting a net loss of $3.6 million on operating expenses of $3.4 million for the six months ended June 30, 2026. The company holds approximately $231,000 in cash, raising substantial doubt about its ability to continue as a going concern without additional financing. On September 14, 2026, NeuroSense effected a one-for-20 reverse stock split. PrimeC, the lead candidate for ALS, achieved primary endpoints in the PARADIGM study and targets a Canadian New Drug Submission in December 2026. The company is also pursuing an optimized U.S. development strategy and strategic alternatives to fund continued operations.